Browse

For the ~1 in 100 people living with celiac, the burden of disease extends far beyond their plate.

For sterile injectables, key early decisions can have a significant impact on the products’ development.

In a wide-ranging interview, Abe Ceesay detailed how Rapport built an investor syndicate and why the company is confident it can join the ranks of successful, commercial-stage brain drugmakers.